These findings were also confirmed by the histopathological analysis of NAFLD Activity Score (Fig. 2B), level of plasma alanine aminotransferase (ALT) (Fig. 2C) and by the analysis of the transcripts for pro-fibrogenic (α-Smooth Muscle Actin, CollagenIα1, Connective Tissue Growth Factor) and pro-angiogenic genes (Vascular Endothelial Growth Factor-A, CD126, Fibroblast Growth Factor-β) (Fig. 2D), which indicated a time-dependent progression of all the main features of liver injury associated with NAFLD. The gene discussed is CCN2; the disease is metabolic dysfunction-associated steatotic liver disease.